Moderna Inc
MRNA29.490USD
-0.920-3.03%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
11.53BMarket Cap
LossP/E TTM
More Details of Moderna Inc Company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Moderna Inc Info
Ticker SymbolMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
CEOBancel (Stephane)
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Ticker SymbolMRNA
IPO dateDec 07, 2018
CEOBancel (Stephane)
Company Executives of Moderna Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.02%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
53.23K
+85.23%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
43.20K
+129.46%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.02%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
53.23K
+85.23%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
43.20K
+129.46%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
COVID
114.00M
0.00%
RSV
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
88.00M
77.19%
Rest of the World
26.00M
22.81%
Europe
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
COVID
114.00M
0.00%
RSV
0.00
0.00%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Other
70.73%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.52%
Baillie Gifford & Co.
5.59%
BlackRock Institutional Trust Company, N.A.
5.12%
State Street Investment Management (US)
4.38%
Two Sigma Investments, LP
3.66%
Other
70.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.41%
Investment Advisor/Hedge Fund
13.92%
Hedge Fund
9.99%
Corporation
4.63%
Research Firm
4.28%
Individual Investor
2.73%
Bank and Trust
1.83%
Venture Capital
1.20%
Pension Fund
1.17%
Other
21.85%
Institutional Shareholding
Updated: 4 hours ago
Updated: 4 hours ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1836
280.09M
71.69%
-39.81M
2025Q3
1925
289.85M
74.21%
-20.82M
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
41.10M
10.52%
-518.17K
-1.24%
Sep 30, 2025
Baillie Gifford & Co.
21.85M
5.59%
-247.46K
-1.12%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
20.00M
5.12%
+358.11K
+1.82%
Sep 30, 2025
State Street Investment Management (US)
17.11M
4.38%
-162.04K
-0.94%
Sep 30, 2025
Two Sigma Investments, LP
14.30M
3.66%
-472.03K
-3.19%
Sep 30, 2025
Fidelity Management & Research Company LLC
12.28M
3.14%
-7.18M
-36.87%
Sep 30, 2025
Geode Capital Management, L.L.C.
9.25M
2.37%
+372.07K
+4.19%
Sep 30, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.36%
--
--
Sep 30, 2025
Theleme Partners LLP
8.07M
2.07%
+200.00K
+2.54%
Sep 30, 2025
Invesco Capital Management LLC
7.29M
1.87%
+1.02M
+16.35%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.72%
Global X Genomics & Biotechnology ETF
3.52%
First Trust NYSE Arca Biotechnology Index Fund
3.4%
Langar Global HealthTech ETF
3.2%
WisdomTree BioRevolution Fund
2.72%
State Street SPDR S&P Biotech ETF
2.19%
VanEck Biotech ETF
1.82%
Invesco S&P 500 Equal Weight Health Care ETF
1.82%
iShares Health Innovation Active ETF
1.72%
ROBO Global Healthcare Technology & Innovation ETF
1.6%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.72%
Global X Genomics & Biotechnology ETF
Proportion3.52%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.4%
Langar Global HealthTech ETF
Proportion3.2%
WisdomTree BioRevolution Fund
Proportion2.72%
State Street SPDR S&P Biotech ETF
Proportion2.19%
VanEck Biotech ETF
Proportion1.82%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.82%
iShares Health Innovation Active ETF
Proportion1.72%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.6%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Moderna Inc?
The top five shareholders of Moderna Inc are:
The Vanguard Group, Inc. holds 41.10M shares, accounting for 10.52% of the total shares.
Baillie Gifford & Co. holds 21.85M shares, accounting for 5.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 20.00M shares, accounting for 5.12% of the total shares.
State Street Investment Management (US) holds 17.11M shares, accounting for 4.38% of the total shares.
Two Sigma Investments, LP holds 14.30M shares, accounting for 3.66% of the total shares.
The Vanguard Group, Inc. holds 41.10M shares, accounting for 10.52% of the total shares.
Baillie Gifford & Co. holds 21.85M shares, accounting for 5.59% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 20.00M shares, accounting for 5.12% of the total shares.
State Street Investment Management (US) holds 17.11M shares, accounting for 4.38% of the total shares.
Two Sigma Investments, LP holds 14.30M shares, accounting for 3.66% of the total shares.
What are the top three shareholder types of Moderna Inc?
The top three shareholder types of Moderna Inc are:
The Vanguard Group, Inc.
Baillie Gifford & Co.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Baillie Gifford & Co.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Moderna Inc (MRNA)?
As of 2025Q4, 1836 institutions hold shares of Moderna Inc, with a combined market value of approximately 280.09M, accounting for 71.69% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.52%.
What is the biggest source of revenue for Moderna Inc?
In FY2025Q2, the COVID business generated the highest revenue for Moderna Inc, amounting to 114.00M and accounting for --% of total revenue.
